Some recovery in pharma and consumer
RJF Q3 results showed a recovery both in the Specialty Pharma (+8%) and Consumer Healthcare divisions (+15%). The former''s performance was mainly due to a recovery in the Derma division (40% sales), while in consumer, sales were very strong in Vitamins and Sleep, and less in OTC products. Pharma technologies suffered, not only due to the lower demand for antibiotics (-20% drop in the industry) but also due to the delay in the manufacturing of the Janssen va ....
29 Oct 2021
Some recovery but still waiting for the vaccine
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Some recovery but still waiting for the vaccine
- Published:
29 Oct 2021 -
Author:
Ruiz Francisco FR -
Pages:
7
Some recovery in pharma and consumer
RJF Q3 results showed a recovery both in the Specialty Pharma (+8%) and Consumer Healthcare divisions (+15%). The former''s performance was mainly due to a recovery in the Derma division (40% sales), while in consumer, sales were very strong in Vitamins and Sleep, and less in OTC products. Pharma technologies suffered, not only due to the lower demand for antibiotics (-20% drop in the industry) but also due to the delay in the manufacturing of the Janssen va ....